Table 4.
Incidence of purported mutations associated with resistance
| NA usage* | V84M (containing) | A181T or S (alone) | V214A (containing) | Q215S (containing) | L217R (containing) | I233V (containing) |
|---|---|---|---|---|---|---|
| LAM | V84M + A181T (1), V84M + M204I (2) V84M + L80I + L180M + M204I (1) V84M + L180M + M204V ± V173L (2) | A181T (2) | V214A + L180M + M204I (3) V214A + L180M + M204V (1) V214A + M204I (2) | Q215S + L180M + M204I (1) | L217R + L180M + M204I (1) | I233V (1) |
| LAM→ADV | V84M + L80I (2), V84M + M204I (1) V84M + L180M + M204I/V (1) V84M + L180M + A181T + M204I + N236T (1) | A181T (14) A181S (1) | V214A + A181T (1) V214A + A181T + N236T (1) V214A + L180M + M204V (1) V214A + V173L + L180M + M204V (1) V214A (3) | – | L217R + L180M + N236T (1) | – |
| LAM→ETV | V84M + T184I (1), V84M + L180M + M204I (1) V84M + L80I + L180M + T184I + M204I/V (1) | – | V214A + M204I (1) | – | – | – |
| LAM→LAM + ADV | V84M + A181T (1), V84M + A181T + V214A (1) V84M + M204I (1), V84M + A181T + M204I (1) | A181T (3) | V214A + A181T (2) V214A + V84M + A181T (1) | – | – | – |
| LAM + ADV→ADV | – | A181T (1) | V214A (1) | – | – | – |
| ADV | V84M (1), V84M + A181T (1) V84M + L80I + A181T + N236T (1) | A181T (11) | V214A + A181T/V + N236T (1) V214A + A181T (1), V214A (4) V214A + A181T + N236T (1) | Q215S + A181V (1) | L217R (1) | I233V + A181T (1) I233V (3) |
| ADV→LdT | V84M + M204I (1) | A181T (5) | V214A + A181T/V + N236T (1) V214A + A181T (1) | – | – | – |
| LdT | – | A181T (1) | – | – | – | – |
| LAM→ADV→ETV | V84M + L180M + M204V (1) V84M + L80I + M204I (1) V84M + L80I + L180M + M204I (1) | – | – | – | – | – |
| LAM→ADV + ETV | V84M + L180M + M204V (1) | – | – | – | – | – |
| LAM→ADV + ETV→ADV | V84M + M204I (1) | – | – | – | – | – |
| Total | 27 | 38 | 26 | 2 | 3 | 5 |
The incidence number of mutations is indicated in bracket. LAM, lamivudine; ADV, adefovir; ETV, entecavir; LdT, telbivudine; NA, nucleos(t)ide analogues.
*Each mono‐ or sequential/combined therapy lasted for ≥3 months.